Date: 2018-05-30
Type of information: Development agreement
Compound: Fc-saxatilin
Company: Celltrion Healthcare (South Korea) Yonsei University Health System (South Korea)
Therapeutic area: Cerebrovascular diseases
Type agreement: development - licensing
Action mechanism:
- antithrombotic drug/fusion protein/integrin agonist. Fc-saxatilin is an Fc-fusion protein of saxatilin, a snake venom disintegrin containing the Arg-Gly-Asp (RGD) motif, that exerts thrombolytic and antiplatelet effects by interacting with multiple integrins on platelets.
- Fc-Saxatilin has been developed by Professor Ji Hoe Heo-led team of the Severance Integrative Research Institute for Cerebral & Cardiovascular Diseases of Yonsei University with funding by the Ministry of Health and Welfare’s Healthcare Technology Research and Development Project. In mouse brain microvascular endothelial cells, hypoxia increased the permeability to FITC-dextran, and this effect was attenuated by Fc-saxatilin treatment. Fc-saxatilin also blocked vascular leakage of Evans Blue in the ischaemic brain induced by middle cerebral artery occlusion in mice.
- Professor Ji Hoe Heo recently published results providing new insights into the mechanism via which Fc-saxatilin, as an integrin antagonist, prevents vascular leakage under ischemic conditions by regulating occludin expression in endothelial tight junctions. (Fc-saxatilin suppresses hypoxia-induced vascular leakage by regulating endothelial occludin expression. Thromb Haemost. 2017 Feb 28;117(3):595-605. doi: 10.1160/TH16-06-0469. Epub 2016 Dec 22.)
Disease: ischemic stroke
Details:
- • On May 30, 2018, Celltrion has signed an agreement with Yonsei University Health System on the joint development and license-in of Fc-Saxatilin, a candidate drug for ischemic strokes in a bid to develop new biopharmaceuticals for cerebrovascular diseases.
- Under the agreement, Celltrion and Yonsei University Health System will conduct joint development for the optimization of the Fc-Saxatilin molecule, after which Celltrion will have an option for the exclusive worldwide license to conduct clinical trials, to obtain approvals, and to commercialize the drug.
Financial terms:
Latest news:
Is general: Yes
